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Defensins, mammalian antimicrobial peptides 
with pluripotent biological activities, are a family of 
cationic cysteine-rich peptides which spectrum of 
action largely depends on their local concentration 
and microenvironment [1]. By the differences in their 
tertiary structure and disulfide bonding, defensins 
are distributed in three families, namely, α-, β- and 
θ-defensin; the places of their expression in the body 
are different: while α-defensins are expressed by 
netrophils/leucocytes, β-defensins are found mainly 
in epithelial cells.
Recently these molecules are recognized also as 
the possible members of antitumor defense arsenal 
due to their ability to cause lyzis of tumor cells [2], and 
immunomodulatory and chemokine activities [3–6], in 
particular, ability to attract immature dendritic cells. 
This important pattern of beta-defensins has been 
tested in few experimental studies, where defensin 
gene was introduced to tumor cells that lack its expres-
sion, and its in vivo expression resulted in suppression 
of tumor growth in vivo [7, 8]. From the other hand, de-
fensins may have positive or negative impact on tumor 
growth due to their proangiogenic properties (murine 
beta-defensin-29 [9]) or antiangiogenic activities 
(HNP-1 and HNP-3 [10]). Moreover, there is a number 
of reports where pro-proliferative action of defensins 
in vitro [11-13] has been demonstrated, or, in contrary, 
no effect of hBD-2 on proliferation has been stated 
[14]. So, the question on possible role of defensins in 
tumorigenesis remains largely unanswered.
The present research continues our studies of the 
functional role of beta-defensin expression in cancer 
cells. For the study, Lewis lung carcinoma (3LL) model 
was chosen. 3LL is an experimental murine tumor model 
widely used in cancer research. 3LL cells are express-
ing murine beta-defensin-2 (mBD-2), the homolog of 
human beta-defensin-1, at a constant moderate level. 
We have introduced an additional copy of mBD-2 gene 
in 3LL cells with the aim to receive its hyperexpression 
to achieve possible suppression of 3LL growth in vivo. 
However, after such manipulation we have received an 
opposite effect: surprisingly, transfection of 3LL cells 
with pcDNA-mBD-2 and pcDNA-Igk-mBD-2 vectors 
resulted in down-regulation of mBD-2 mRNA expression 
in these cells in parallel with acquired higher prolifera-
tive rate and colony forming ability in vitro, and higher 
aggressiveness of experimental tumors that arised 
from the cells with suppressed mBD-2 expression. 
Taken together, such results are pointing on a possible 
tumor-suppressor role of mBD-2.
MATERIALS AND METHODS
Cell lines and bacterial strains. In vitro culture 
of Lewis lung carcinoma (3LL) cells was obtained from 
the Bank of Cell Lines from Human and Animal Tissues 
of R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology NAS of Ukraine (Kyiv, 
Ukraine). The cells were cultivated in vitro in DMEM 
culture medium with high glucose content supple-
mented with 10% fetal bovine serum, 100 units/mL 
penicillin G sodium, 100 μg/mL streptomycin sulfate 
and 0.25 μg/mL amphotericin B as fungizone in 5% 
CO2 athmosphere at 37 °C.
For testing the antimicrobial activity of recombinant 
mBD-2 in the test of Hultmark et al. [15], Pseudomonas 
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aeruginosa ATCC 9027 was used; the strain was kindly 
gifted by Dr. E. Kiprianova from the D.K. Zabolotny 
Institute of Microbiology and Virology NAS of Ukraine 
(Kyiv, Ukraine).
Generation and purification of recombinant 
mBD-2. To clone the gene coding mature mBD-2 
molecule, mBD-2 cDNA was received by RT-PCR 
with the use of specific primers (mBD-2-F: 5`-ACCG-
GATCCACCATGGAA CTTGACCACTGCCACACC-3` 
mBD-2-R: 5`-GCCGAATTCTCATTTCAT GTACTTG-
CAACAGGG-3`) from total RNA isolated from murine 
BALB/c macrophages incubated for 24 h with 10 ng/ml 
lipopolysaccharides of P. aeruginosa. Primers were 
designed on the base of AJ011800 sequence from 
GenBank database. 
For production of recombinant mBD-2, we have 
chosen the GST-expression system, that allows  the 
production of recombinant proteins fused with gluta-
thione-S-transferase (GST) in bacterial cells upon in-
duction of isopropyl-β-D-thiogalactopiranoside (IPTG). 
Respectively, mBD-2 cDNA fragment was cloned 
in pGEX-2T vector by BamHI and EcoRI sites using 
routine procedure. PCR product and pGEX-2T vector 
were purified, treated with restriction endonucleases 
BamHI and EcoRI, ligated by routine technique, and 
correctness of insertion was verified by the DNA dide-
oxy sequencing method and restriction analyzis. Then 
E. coli BL21DE3 cells were routinely transformed with 
this vector, the selection of clones was performed 
as described elsewhere. Recombinant mDD-2 was 
isolated from bacterial cells by means of affine chro-
matography on Glutathione-Sepharose (Sigma, USA) 
with the next proteolysis of GST-mBD-2 fusion protein 
with thrombin and reverse phase chromatography on 
Sep-Pack C18 (Waters, USA) carrier similarly to the 
procedure described earlier for recombinant human 
beta-defensin-2 [16].
Gene cloning, plasmid constructions and 
transfection of 3LL cells. The gene coding mature 
murine β-defensin-2 was cloned from total RNA 
isolated from murine BALB/c macrophages incu-
bated for 24 h with 10 ng/ml lipopolysaccharides of 
P. aeruginosa and cDNA was amplified by RT-PCR 
using specific primers (mBD-2-F: 5`-ACCTAAGCT-
TCGAACTTGACCACTGCCACACC-3` and mBD-2-R: 
5`-GGCGAATTCTCATTTCATGTACTTGCAACAGGG-3). 
The PCR products were digested with HindIII and EcoRI 
and cloned into the same sites of expression vector 
pcDNA3.1+, which contained a selective marker — the 
neomycin phosphotransferase gene. The constructs 
were verified by the DNA dideoxy sequencing method 
and purified using a standard protocol. 
To receive a variant for secreted form of mBD-2, 
leader sequence of Igk gene was recloned from pSec-
Tag2A vector (Invitrogene) and placed into pcDNA3.1+ 
vector before mBD-2 sequence.
The resulting constructs were transfected into 
3LL cells using FuGENE 6 Reagent (Roche Molecular 
Biochemicals) according to the instructions of the 
manufacturer. 
After transfection, the cells were selected in the 
medium containing 600 μg/mL geneticin G418 (Gibco, 
Grand Island, NY, USA) for 2 weeks, and stable cell sub-
lines 3LL-pcDNA3 (transfected with blank pcDNA3 vec-
tor), 3LL-mBD2 (expressing mBD2) and 3LL-Igk-mBD2 
(carrying secreted form of mBD2) were obtained.
RT-PCR analysis of mBD2 expression. Total 
RNA was isolated from tissue samples by the method 
of Chromzynski and Sacchi [17]. Concentration of 
RNA was evaluated at the wave length of 260 nm using 
Beckman DU-8B spectrophotometer, its purity — by 
OD relation at 280 nm and 260 nm, its quality — by 
electrophoresis in 1% agarose gel containing 20% 
formaldehyde. For detection of mBD-2 RNA expres-
sion, semiquantitive RT-PCR analysis was performed 
with the use of specific primers. The expression level 
of beta-actine served as the house-keeping gene. 
The products of RT-PCR were routinely analyzed by 
electrophoresis in agarose gel. The relative expression 
level was analyzed with the use of TotalLab Program.
3H-thymidine incorporation. To evaluate cell 
proliferation rate, radioisotope method was routinely 
applied as described elsewhere [18]. Shortly, the 
cells (1 x 105 cells/well) were grown on 24-well plate 
in DMEM for 24 h. Then 0.1 μCi-3H-thymidine per well 
was added, and the cells were incubated for 16 h. The 
radioactivity of the cells was measured according 
standard procedure using scintillation beta counter 
Beckman 5801 LS.
Colony formation analysis. Analysis of colony 
forming ability of the cells was carried out by routine 
technique as described elsewhere [19] in DMEM me-
dium supplemented with 15% FBS and 0.4% methyl-
cellulose. The cells were plated in 6-well plates (1 х 
103 cells per 1 ml of medium) and incubated in СО2-
incubator for 14–16 days. The colonies were visualized 
using staining procedure with 0.2% p-iodonitrotetra-
zolium violet dye and counted.
In vivo study. For in vivo research, male C57BL 
mice weighing 20–25 g bred in the vivarium of 
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology NAS of Ukraine (Kyiv, 
Ukraine) were used. All animal procedures were carried 
out according to the rules of local Ethic Committee and 
were approved by the Ethic Board.
3LL cells and transfected cell sublines were trans-
planted i.m. ((3 x 105 cells/100 μl PBS per animal) to 
C57BL mice mice. Animals were housed in 4 groups 
(5 mice per group): animals with transplanted wild-
type 3LL cells (group 1), 3LL-pcDNA3 cells (group 2), 
3LL-mBD2 cells (group 3), and 3LL-Igk-mBD2 cells 
(group 4). Tumor growth dynamics was monitored 
each week for 3 weeks by means of calipers. At the day 
21 after tumor cell transplantation, the animals were 
sacrificed by ether narcosis, tumors were removed 
and weighted, and lung metastases were calculated. 
By this scheme, 3 independent in vivo experiments 
were performed.
Statistical analysis. The data are reported as the 
mean ± SD. The statistical significance of differences 
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between mean values was assessed by the Student’s 
t-test. Values p < 0.05 were considered statistically 
significant.
RESULTS
Generation of recombinant mBD-2. For pro-
duction of recombinant mBD-2, the GST-expression 
system was chosen. Respectively, recombinant 
mBD-2 fused with GST was isolated from transformed 
bacterial cells by means of affine chromatography on 
Glutathione-agarose with the next proteolysis of GST-
mBD-2 fusion protein with thrombin and reverse phase 
chromatography on Sep-Pack C18 carrier (Fig. 1, a) 
similarly to the procedure described earlier for recom-
binant human beta-defensin-2. The obtained mBD-2 
protein was demonstrated to be active in micromolar 
concentrations against P. aeruginosa (Fig. 1, b).
fig. 1. a, Electrophoretic analysis of purity of the recombinant 
mBD-2 preparation after reverse phase chromatography on 
Sep-Pack C18. Line 1 — molecular weight markers (Fermentas, 
Lietuva); lines 2 and 3 — elution with 30% CH3CN and 40% 
CH3CN, respectively. b, Antimicrobial activity of recombinant 
mBD-2 against P. aeruginosa: 1, 2, 3 — 1, 3 and 5 μM mBD-2 
So, in this first part of our work, recombinant antimi-
crobially active mBD-2 was obtained for some special 
tasks of the further research.
Generation of pcDNA3-Igk-pcDNA3 vectors, 
transfection of 3LL cells and expression of mBD-2 
mRNA in vitro. At the first stage of the research, us-
ing standard cloning technique, we have created two 
vectors at the base of pcDNA3.1+: pcDNA3-mBD-2 
and pcDNA3-Igk-mBD-2 that codes mature mBD-2 
molecule and its secreted form, respectively. These 
vectors and blank control pcDNA3.1+ vector were used 
for the transfection of 3LL cells. After selection on G418 
containing medium, the transfected cells were multi-
plied and analyzed for expression of mBD-2 mRNA.
3LL cells are expressing mBD-2 mRNA at a con-
stant moderate level. Performing such transfection, 
we supposed that overexpression of mBD-2 mRNA 
in 3LL cells will be achieved. Surprisingly, finally we 
have observed quite the opposite effect: in the cells 
transfected with pcDNA3-mBD-2 and pcDNA3-Igk-
mBD-2 (3LL-mBD2 and 3LL-Igk-mBD2 respectively), 
a notable down-regulation of mBD-2 gene was regis-
tered (Fig. 2), while in the cells transfected with a blank 
vector this parameter did not differ significantly from 
that in parental 3LL cells (p < 0.01). 
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fig. 2. a, RT-PCR analysis of mBD-2 gene expression in 3LL cells 
(2), 3LL-mBD2 cells (3), 3LLIgk-mBD2 cells (4), 3LL-pcDNA3 
cells (5); line 1 — DNA standard 50 bp ladder (Fermentas, Lie-
tuva) (a). Expression of beta-actine as house-keeping gene (b). 
b, The data of mBD-2 gene expression in transfected cells are 
normalized by beta-actine expression using TotalLab program
To find out whether down-regulation of mBD-2 
gene may be caused by its own protein product, we 
have performed in vitro culturing of wild-type 3LL cells 
with exogeneously added 0.1 and 1.0 μg/ml recombi-
nant mBD-2 in serum-free medium for 24 h and 48 h. 
Then the cells were lyzed, total RNA was isolated, and 
semi-quantative RT-PCR analyzis was carried out. 
Similarly to the above-mentioned data, in the cells cul-
tivated with recombinant mBD-2 significant decrease 
of mBD-2 mRNA was detected, and mBD-2 mRNA was 
nearly undetectable after 48 h incubation of 3LL cells 
with 1.0 μg/ml recombinant mBD-2 (Fig. 3). 
So, on the base of 3LL cells expressing mBD-2 
mRNA we have generated the cell sublines 3LL-mBD2 
and 3LL-Igk-mBD2 where expression of mBD-2 is 
strongly down-regulated, possibly, by the feedback 
mechanism. So, it looked reasonable to check the 
patterns of 3LL cells with down-regulated mBD-2 gene 
compared with parental strain. 3LL cells are widely 
used in vivo for generation of aggressive experimental 
murine tumors with high metastatic activity resulting 
in multiple lung metastases. So, we have checked the 
proliferative rate and colony forming capacity of sub-
lines 3LL-mBD2 and 3LL-Igk-mBD2 compared to wild 
type 3LL cells as well as the growth dynamics of tumors 
that arised from transplanted 3LL cell sublines.
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fig. 3. RT-PCR analysis of mBD-2 gene expression in 3LL cells 
incubated in vitro with the recombinant mBD-2.  Lines: 1 — DNA 
standard 50 bp ladder (Fermentas, Lietuva); 2–6 — expression 
of beta-actine as house-keeping gene; expression of mBD-2 in 
control 3LL cells (7), 3LL cells induced by 0.01 μg/ml mBD-2 for 
24 h (8), 0.01 μg/ml mBD-2 for 48 h (9); 1 μg/ml mBD-2 for 24 h 
(10), 1 μg/ml mBD-2 for 48 h (11)
Colony formation and proliferation rate of 
3LL cells transfected with pCDNA3- pcDNA3 
and pCDNA3-Igk-pcDNA3plasmids. Ability to 
form colonies in a semi-soft medium is an important 
characteristic of cell culture indicating its tumotigenic 
potential.  The analysis of ability of 3LL, 3LL-pcDNA3, 
3LL-mBD2 and 3LL-Igk-mBD2 cells to form colonies in 
0.4% methylcellulose has demonstrated that the cells 
where expression of mBD-2 gene is down-regulated, 
formed significantly higher number of colonies than 
those where expression of mBD-2 mRNA is not af-
fected, and that 3LL-mBD2 and 3LL-Igk-mBD2 cells 
gave rise to larger colonies than 3LL and 3LL-pcDNA3 
did (Table).
Table. Colony forming activity of 3LL cells and 3LL-mBD2 and 3LL-Igk-
mBD2 sublines
Cell line Number of colonies Colony size 
3LL < 20 < 10 cells
3LL-pcDNA3 < 20 < 10 cells
3LL-mBD2 > 50 > 10 cells
3LL-Igk-mBD2 > 50 > 10 cells
Analysis of 3H-thymidine incorporation in DNA of 
3LL, 3LL-pcDNA3, 3LL-mBD2 and 3LL-Igk-mBD2 
cells has shown that 3LL-mBD2 and 3LL-Igk-mBD2 
are characterized by significantly higher proliferation 
rate (p < 0.001) than the control cells, while this index 
did not differ significantly between wild-type 3LL cells 
and the cells transfected with the blank vector (p > 
0.05) (Fig. 4). 
So, our data have indicated an existence of reverse 
relation between colony-forming activity and prolifera-
tion potential of 3LL cells and the level of mBD-2 mRNA 
expression. The next question to be answered was 
whether such properties will influence the develop-
ment and growth dynamics of experimental 3LL tumors 
that arise from trasfected 3LL cells.
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fig. 4. Analysis of 3H-thymidine incorporation in the DNA of 
3LL, 3LL-pcDNA3, 3LL-mBD2 and 3LL-Igk-mBD2 cells. The data 
(Mean ± SD) of two independent experiments performed in four 
parallels each are presented
*p < 0.001 compared to 3LL.
Influence of mBD-2 expression on the growth 
dynamics of experimental murine tumors. To an-
swer this question, 3LL, 3LL-pcDNA3, 3LL-mBD2 and 
3LL-Igk-mBD2 cells were routinely transplanted (3 x 
105 cells per animal) in C57 Black mice, and tumor 
growth dynamics was monitored each week during 
21 days period. Our data have shown that the tumors 
that arised from 3LL-mBD2 and especially from 3LL-
Igk-mBD2 cells possessed significantly higher growth 
rate that was nearly 1.5-fold and 1.7-fold higher than 
that of 3LL- and 3LL-pcDNA3-derived tumors (p < 
0.05) (Fig. 5), while 3LL- and 3LL-pcDNA3 tumors 
did not differ significantly in the growth dynamics (p > 
0.05). At the day 21 after tumor cell transplantation, 
the metastatic rate was high in all 4 studied groups, 
and it was impossible to make correct comparisons 
between the groups; however, there was observed a 
tendency for more aggressive metastasis in the case 
of 3LL-Igk-mBD2-derived tumors (data not shown).
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fig. 5. Relative weight of the tumors derived from transplanted 
3LL, 3LL-pcDNA3, 3LL-mBD2 and 3LL-Igk-mBD2 cells at the 
day 21 after tumor cell transplantation. The data (Mean ± SD) 
of three independent experiments are presented
*p < 0.01 compared to 3LL.
So, these results have demonstrated that down-
regulation of mBD-2 gene expression resulted in 
acceleration of the development of experimental 
murine tumors; which, taking into account the above-
mentioned data on in vitro consequences of mBD-2 
down-regulation, may suggest a tumor-suppressing 
role of murine beta-defensin-2 expression. 
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DIScUSSION
During the last few years, the defensins became 
a subject of intensive research due to their recently 
revealed multiple biological activities that allow to con-
sider them not only as an important component of host 
antibacterial defense, but as an agents influencing 
tumorigenesis as well. First of all, in vitro studies have 
shown mitogenic action of defensins, for example, 
pro-proliferative effects of alpha- and beta-defensins 
(HNP-1 and hBD-2) at micromolar concentration range 
toward conjunctival fibroblasts [20] and airway epithe-
lial cells [11]; similar data were reported in our earlier 
publications where we have shown a dose-dependent 
mitogenic effect of hBD-2 on human cancer A431 and 
HeLa cells [13]. However, there are also reports where 
0.1–10 μg hBD-2 has no influence of proliferation rate 
of intestinal epithelial cells, but strongly promotes 
epithelial cell survival [14]. 
In the present study, we have introduced an ad-
ditional copy of mBD-2 gene in 3LL cells with an aim 
to receive its hyperexpression to achieve possible 
suppression of 3LL growth in vivo, but received quite 
the opposite effect and revealed an interesting phe-
nomenon: if expression of mBD-2 gene was down-
regulated, 3LL cancer cells acquire significantly higher 
proliferative rate (p < 0.001). Moreover, such aggres-
sive growth pattern was analogous in vivo, when these 
cells with down-regulated mBD-2 gene gave rise to 
experimental tumors. We propose a hypothesis that in 
fact mBD-2 may play a role of anti-mitogenic molecule 
that, being expressed at physiologically normal low 
level, protects cells from excessive proliferation. Some 
evidence presented in this report point to the existence 
of some kind of a feedback mechanism: excessive 
defensin production may result in the down-regulation 
of its own gene, allowing in turn the cell proliferation. 
In our earlier studies we did not check expression 
levels of hBD-2 in the A431 and HeLa cells treated with 
extracellular defensin; it could not be excluded that 
in the case of hBD-2 the mechanism of action could 
be similar. In part, such hypothesis is supported by 
our research of human embryonal kidney (HEK293) 
cells transfected with Igk-hBD-2-containing vector 
(not published data): if wild-type cells do not express 
hBD-2 and possess high proliferative rate and high 
colony forming activity, transfected cells are express-
ing picomolar concentrations of hBD-2 and largely lost 
colony formation ability along with decreased prolifera-
tion rate. Of course, such hypothesis requires further 
more intense studies for its support. At the same time, 
these unexpected data received in in vitro and in vivo 
models are in agreement with an opinion about pos-
sible tumor-suppression functions of defensins [21] 
delineated from a number of recent studies including 
those carried on human prostate and renal tumors [7]. 
Fundamental studies of defensin signaling machinery 
will strongly facilitate our knowledge on exact func-
tional role of these antimicrobials in cancer cells.
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СНИЖЕНИЕ УРОВНЯ ЭКСПРЕССИИ БЕТА-ДЕФЕНСИНА-2 
МЫШИ В КЛЕТКАХ КАРЦИНОМЫ ЛЕГКИХ ЛЬЮИС ПРИВОДИТ 
К  УСКОРЕНИЮ РОСТА ОПУХОЛЕВЫХ КЛЕТОК IN VITRO И IN VIVO
Цель: настоящая работа посвящена анализу противоопухолевых свойств бета-дефенсина-2 мыши (mBD-2) in vitro and in 
vivo. Материалы и методы: на основе pcDNA3.1+ вектора были созданы 2 плазмидных конструкта, кодирующих зрелую 
форму mBD-2, содержащие или несодержащие сигнальную последовательность Igk (pcDNA3mBD-2 и pcDNA3Igk-mBD-2 
соответственно). Путем трансфекции клеток 3LL полученными векторами, а также контрольным вектором pcDNA3.1+ 
были получены клеточные линии (3LL-mBD-2, 3LL-Igk-mBD-2 и 3LL-pcDNA3), для которых были проведены иссле-
дования их пролиферативной активности, определенной по уровню включения 3Н-тимидина в ДНК, и способности к 
колониеобразованию в среде, содержащей метилцеллюлозу. Экспрессию гена mBD-2 исследовали с помощью полуколи-
чественного ОТ-ПЦР-анализа. Трансфецированные клетки были имплантированы мышам линии C57BL, после чего была 
проанализирована динамика роста опухоли. Результаты: установлено, что в трансфектных клеточных линиях 3LL-mBD-2 
и 3LL-Igk-mBD-2 уровень экспрессии mBD-2 снижен по сравнению с контрольными. Эти клетки характеризовались до-
стоверным повышением уровня пролиферации (р < 0,001) и способности к колониеобразованию. Клетки сублиний 3LL-
mBD-2 и 3LL-Igk-mBD-2, трансплантированные мышам линии C57BL, вызывали развитие более агрессивных опухолей, 
обладающих значительно более высокой скоростью роста (p < 0,01), чем таковые, вызванные перевивкой клеток 3LL. 
Выводы: полученные результаты свидетельствуют о возможной роли mBD-2 как опухолевого супрессора.
Ключевые слова: бета-дефенсин-2 мыши, карцинома легких Льюис (3LL), экспрессия, пролиферация, колониеобразование.
